Rigel Pharmaceuticals, Inc. experienced a substantial financial improvement in the first quarter of 2025, with total revenues increasing by 80% and net income reaching $11.4 million, a significant turnaround from a net loss in the prior year period. This growth was primarily fueled by increased product sales of TAVALISSE, REZLIDHIA, and the new commercialization of GAVRETO, alongside higher contract revenues from collaborations.

Rigel reported record net product sales of $144.9 million, a 39% increase compared to 2023, and generated full-year net income of more than $17 million.

Rigel Pharmaceuticals reported a net income of $12.4 million for the third quarter of 2024, with total revenues of $55.3 million. The company's growth was driven by increased sales of TAVALISSE, REZLIDHIA, and GAVRETO, as well as contract revenue from collaborations.

Rigel Pharmaceuticals reported total revenues of $36.8 million for the second quarter of 2024, driven by record sales of TAVALISSE and REZLIDHIA, as well as the addition of GAVRETO to their commercial portfolio. The company reported a net loss of $1.0 million, approaching net income break even.

Rigel Pharmaceuticals reported Q1 2024 financial results, featuring strong commercial demand with record bottle sales for TAVALISSE and REZLIDHIA. Total revenues reached $29.5 million, with a net loss of $8.2 million, or $0.05 per share.

Rigel Pharmaceuticals reported a net income of $0.7 million for the fourth quarter of 2023, with total revenues of $35.8 million driven by TAVALISSE and REZLIDHIA sales and collaboration revenues.

Rigel Pharmaceuticals reported a net loss of $5.7 million on total revenues of $28.1 million for Q3 2023. Revenue was driven by TAVALISSE net product sales of $24.5 million and REZLIDHIA net product sales of $2.7 million.

Rigel Pharmaceuticals reported a net loss of $6.6 million for the second quarter of 2023, with total revenues of $26.9 million. TAVALISSE net product sales increased by 15% year-over-year, and the company continued to advance its development programs.

Rigel Pharmaceuticals reported a net loss of $13.5 million for the first quarter of 2023, with total revenues of $26.1 million. The company saw a 47% increase in net product sales compared to Q1 2022, driven by TAVALISSE and REZLIDHIA sales.

Rigel reported a net income of $1.4 million for the fourth quarter of 2022, with total revenues of $51.3 million, including sales of TAVALISSE® and REZLIDHIA™.

Rigel Pharmaceuticals reported a net loss of $19.0 million for the third quarter of 2022. Total revenues were $22.4 million, including $19.2 million in TAVALISSE net product sales, which increased by 20% compared to the same period in 2021.

Rigel Pharmaceuticals reported a net loss of $13.5 million for Q2 2022, with total revenues of $29.8 million. TAVALISSE net product sales increased by 9% to $18.6 million, and contract revenues from collaborations totaled $11.3 million.

Rigel Pharmaceuticals reported a net loss of $27.4 million for the first quarter of 2022. Total revenues were $16.7 million, including $16.2 million in TAVALISSE net product sales. TAVALISSE sales increased by 31% compared to the first quarter of 2021.

Rigel Pharmaceuticals reported a net loss of $22.6 million for the fourth quarter of 2021, with total revenues of $20.4 million, including $17.6 million from TAVALISSE net product sales and $2.8 million from contract revenues. The company's costs and expenses increased to $41.8 million due to research and development and commercial activities.

Rigel Pharmaceuticals reported a net loss of $21.0 million, or $0.12 per basic and diluted share, with total revenues of $21.5 million. TAVALISSE net product sales were $16.0 million, a decrease of 2% from the same period in 2020.

Rigel Pharmaceuticals reported a net loss of $13.8 million for the second quarter of 2021, with total revenues of $26.3 million, including TAVALISSE net product sales of $17.1 million.

Rigel Pharmaceuticals reported a net income of $39.5 million for the first quarter of 2021, with total revenues of $81.0 million. The company is advancing its clinical programs, including fostamatinib for COVID-19 and IRAK1/4 program.

Rigel Pharmaceuticals reported Q4 2020 financial results, including a net loss of $19.2 million, or $0.11 per share. Total revenues were $18.5 million, with TAVALISSE net product sales increasing by 28% to $17.8 million.

Rigel Pharmaceuticals reported third quarter total revenues of $18.4 million, including net product sales of $16.3 million, a 39% year-over-year increase. The company's net loss was $14.2 million, or $0.08 per share.

Rigel Pharmaceuticals reported second quarter results with net product sales of $15.0 million, a 47% year-over-year increase. The company experienced a net loss of $17.6 million, or $0.10 per share. They also appointed David Santos as Chief Commercial Officer and progressed their pipeline, including a Phase 2 trial for COVID-19 pneumonia.

Rigel Pharmaceuticals reported a net income of $21.2 million for the first quarter of 2020, with total revenues of $55.8 million, including $12.7 million in net product sales and $43.1 million in contract revenues from collaborations.

Rigel reported fourth quarter total revenues of $15.4 million, with net product sales of $13.8 million. The company's net loss for the quarter was $17.2 million, or $0.10 per share.